By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.

Market OverviewThe Global Breast Cancer Therapeutics Market  remains one of the most prevalent forms of cancer worldwide, ...

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.

India's pharma market has introduced 3,151 new brands in the past year, with AstraZeneca's cancer drug Enhertu becoming the ...

With the rising incidence of cancer in India, AstraZeneca India's breast cancer medicine trastuzumab deruxtecan (sold under ...

Shares of solid tumor concern Zymeworks Inc. have barely budged since the company obtained its first approval. Click here to read why ZYME stock is a Hold.

Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs ...

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

AZ booked $540 million from Enhertu in the fourth quarter, a rise of 54%, and $1.99 billion for the full year out of total ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...